Product Description
a novel multitarget antihypertensive agent (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33782540/)
Mechanisms of Action: ADRA1 Blocker, 5-HT2A Blocker, Calcium Channel Blocker Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Liaoning Green Biopharmaceutical Group Co., Ltd./Shenyang Neptune Biotechnology Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hypertension
Phase 1: Healthy Volunteers|Hypertension
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20220993 |
CTR20220993 | P2 |
Completed |
Hypertension |
2023-02-22 |
2025-04-29 |
Patient Enrollment|Treatments |
|
ChiCTR2000038948 |
ChiCTR2000038948 | N/A |
Recruiting |
Hypertension |
2021-06-30 |
|||
ChiCTR1900025054 |
ChiCTR1900025054 | N/A |
Recruiting |
Hypertension |
2020-06-30 |
|||
ChiCTR2200060328 |
ChiCTR2200060328 | N/A |
Not yet recruiting |
Hypertension |
None |
2023-03-19 |
Treatments |
|
ACTRN12621001370897p |
2006-7041-83/hah | N/A |
Not yet recruiting |
Shoulder Pain|Musculoskeletal Pain |
2022-05-31 |
|||
CTR20191573 |
CTR20191573 | P1 |
Completed |
Healthy Volunteers |
2020-05-09 |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20253004 |
CTR20253004 | P1 |
Unknown |
Hypertension |
None |
2026-05-17 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20201993 |
CTR20201993 | P1 |
Completed |
Hypertension |
2021-05-06 |
2025-04-29 |
Recent News Events
Date |
Type |
Title |
|---|